According to Jazz Pharmaceuticals's latest financial reports the company's current EPS (TTM) is -$1.41. In 2022 the company made an earnings per share (EPS) of -$3.54 an increase over its 2021 EPS that were of -$5.38.
Year | EPS | Change |
---|---|---|
2023 (TTM) | -$1.41 | -60.17% |
2022 | -$3.54 | -34.2% |
2021 | -$5.38 | -224.83% |
2020 | $4.31 | -53.25% |
2019 | $9.22 | 23.59% |
2018 | $7.46 | -8.24% |
2017 | $8.13 | 23.74% |
2016 | $6.57 | 22.12% |
2015 | $5.38 | 478.49% |
2014 | $0.93 | -74.93% |
2013 | $3.71 | -27.11% |
2012 | $5.09 | 69.1% |
2011 | $3.01 | 245.98% |
2010 | $0.87 | -462.5% |
2009 | -$0.24 | -96.7% |
2008 | -$7.28 | -27.04% |
2007 | -$9.98 | 65.47% |
2006 | -$6.03 | -4.59% |
2005 | -$6.32 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
![]() Novartis NVS | $3.62 | -356.74% | ๐จ๐ญ Switzerland |
![]() AmerisourceBergen
ABC | $8.29 | -687.94% | ๐บ๐ธ USA |
![]() Endo International
ENDPQ | -$4.02 | 185.11% | ๐ฎ๐ช Ireland |
![]() Teva Pharmaceutical Industries TEVA | -$2.00 | 41.84% | ๐ฎ๐ฑ Israel |